Zentalis Pharmaceuticals, Inc. (ZNTL): who owns it and who trades it
As of Nov 16, 2026, ZNTL insiders reported 10 open-market sales worth $10.1M and 2 purchases worth $22.9M in the last 12 months, with 1% of the sale value made under pre-set 10b5-1 plans. The largest seller was David E. Goel (10% owner), with $10M. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Zentalis Pharmaceuticals
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ZNTL
114 funds and institutions reported ZNTL shares worth $230M at the end of Q2 2026, about 67% of the company. The largest holder is 5AM Venture Management, LLC with 5.6%.
Funds and institutions (13F) 67%Everyone else 33%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| 5AM Venture Management, LLC | 3.95M | 5.57% | $19.1M | No change |
| BlackRock, Inc. | 3.75M | 5.29% | $18.2M | +196% |
| Squadron Capital Management LLC | 3.70M | 5.22% | $17.9M | +2% |
| Two Sigma Investments, LP | 3.02M | 4.26% | $14.7M | +2% |
| Vanguard Capital Management LLC | 2.84M | 4.00% | $13.8M | +23% |
| Acadian Asset Management LLC | 2.68M | 3.78% | $13M | -6% |
| Citadel Advisors LLC | 2.30M | 3.24% | $11.1M | +33% |
| Renaissance Technologies LLC | 1.61M | 2.27% | $7.8M | -17% |
| Opaleye Management Inc. | 1.41M | 1.99% | $6.9M | No change |
| Orbimed Advisors LLC | 1.39M | 1.96% | $6.7M | – |
| Decheng Capital LLC | 1.32M | 1.87% | $6.4M | No change |
| Geode Capital Management, LLC | 1.28M | 1.81% | $6.2M | +107% |
| Bank of America Corp | 1.11M | 1.57% | $5.4M | -2% |
| Ishara Investments LP | 1.02M | 1.45% | $5M | -17% |
| Primecap Management Co | 957,420 | 1.35% | $4.6M | No change |
| Pfizer Inc | 953,834 | 1.34% | $3.9M | No change |
| Soleus Capital Management, L.P. | 950,000 | 1.34% | $4.6M | – |
| State Street Corp | 887,416 | 1.25% | $4.3M | +255% |
| Vanguard Portfolio Management LLC | 808,548 | 1.14% | $3.9M | +124% |
| Connor, Clark & Lunn Investment Management Ltd. | 758,033 | 1.07% | $3.7M | -4% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, ZNTL insiders reported $22.9M of open-market purchases and $10.1M of sales. 1% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | William Thurman Walters +2 | 10% owner | Purchase | 4.33M | $3.50 | $15.2M | Form 4 |
| Feb 10, 2026 | Vincent Vultaggio | PAO and PFO | Sale plan | 6,894 | $2.42 | $16.7K | Form 4 |
| Feb 9, 2026 | Ingmar Bruns | Chief Medical Officer | Sale | 335 | $2.39 | $801 | Form 4 |
| Feb 9, 2026 | Vincent Vultaggio | PAO and PFO | Sale plan | 3,379 | $2.39 | $8.1K | Form 4 |
| Feb 9, 2026 | Julia Marie Eastland | CEO | Sale | 889 | $2.39 | $2.1K | Form 4 |
| Feb 6, 2026 | Ingmar Bruns | Chief Medical Officer | Sale | 2,962 | $2.43 | $7.2K | Form 4 |
| Feb 6, 2026 | Vincent Vultaggio | PAO and PFO | Sale plan | 29,951 | $2.43 | $72.8K | Form 4 |
| Feb 6, 2026 | Julia Marie Eastland | CEO | Sale | 7,866 | $2.43 | $19.1K | Form 4 |
| Feb 3, 2026 | Vincent Vultaggio | PAO and PFO | Sale plan | 556 | $2.52 | $1.4K | Form 4 |
| Feb 2, 2026 | Vincent Vultaggio | PAO and PFO | Sale plan | 2,540 | $2.55 | $6.5K | Form 4 |
| Dec 31, 2025 | William Thurman Walters +2 | 10% owner | Purchase | 6.46M | $1.20 | $7.8M | Form 4 |
| Dec 15, 2025 | David E. Goel +1 | 10% owner | Sale | 7.50M | $1.33 | $10M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| William Thurman Walters | 10% owner | $22.9M | – | Aug 14, 2026 |
| David E. Goel | 10% owner | – | $10M | Dec 15, 2025 |
| Vincent Vultaggio | PAO and PFO | – | $105K | Feb 10, 2026 |
| Julia Marie Eastland | CEO & President, Director | – | $21.2K | Feb 9, 2026 |
| Ingmar Bruns | Chief Medical Officer | – | $8K | Feb 9, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ZNTL short interest
Moderate short interest. 7.0% of ZNTL shares are sold short: about 1 share in 14. Over the last 12 reports the number of shares short went up 2%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 5.04M ZNTL shares were sold short, 7.0% of the shares outstanding, down 15.9% from the report before. At the average daily volume of 1.44M shares, buying them all back would take about 3.5 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 5.04M | 7.03% | -16% | 1.44M | 3.5 |
| Oct 15, 2026 | 5.99M | 8.35% | +0% | 1.25M | 4.8 |
| Sep 30, 2026 | 5.96M | 8.31% | +24% | 1.44M | 4.1 |
| Sep 15, 2026 | 4.79M | 6.68% | -4% | 913,636 | 5.2 |
| Aug 31, 2026 | 4.99M | 6.96% | -16% | 972,282 | 5.1 |
| Aug 14, 2026 | 5.97M | 8.33% | +7% | 1.12M | 5.3 |
| Jul 31, 2026 | 5.58M | 7.86% | -9% | 1.34M | 4.2 |
| Jul 15, 2026 | 6.15M | 8.67% | +5% | 971,501 | 6.3 |
| Jun 30, 2026 | 5.87M | 8.27% | +18% | 1.82M | 3.2 |
| Jun 15, 2026 | 4.98M | 7.02% | -1% | 883,180 | 5.6 |
| May 29, 2026 | 5.02M | 7.08% | +2% | 984,219 | 5.1 |
| May 15, 2026 | 4.92M | 6.94% | -10% | 889,372 | 5.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Zentalis Pharmaceuticals company events
Zentalis Pharmaceuticals filed 13 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 9, 2026.
- Nov 9, 2026ResultsReleased financial results. Filing
- Aug 14, 2026AnnouncementZentalis Pharmaceuticals, Inc. entered into an underwriting agreement with TD Securities (USA) LLC, Guggenheim Securities, LLC and Oppenheimer & Co. Inc., as representatives of the several underwriters named therein, in connection with the offering, issuance and sale by the Company of 23,000,000… Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jun 18, 2026VoteReported shareholder vote results. Filing
- May 27, 2026LeadershipThe Board of Directors of Zentalis Pharmaceuticals, Inc. increased its size from six to seven directors and appointed Shannon Campbell, as a Class I director. Filing
- May 21, 2026AnnouncementZentalis Pharmaceuticals, Inc. announced that data from Part 1 of the Phase 1b MUIR trial will be presented at the 2026 American Society of Clinical Oncology Annual Meeting, being held May 29 – June 2, 2026, in Chicago, Illinois. Filing
- May 12, 2026ResultsReleased financial results. Filing
- May 5, 2026AnnouncementThe Company announced that the first patient has been dosed in the Phase 3 ASPENOVA clinical trial evaluating azenosertib in patients with Cyclin E1-positive platinum-resistant ovarian cancer. Filing
- Apr 17, 2026AnnouncementShared information with investors. Filing
- Apr 9, 2026AnnouncementThe Company announced the selection of 400mg once daily on a 5-days-on, 2-days-off schedule (400mg QD 5:2) as the optimal monotherapy dose of azenosertib in patients with Cyclin E1-positive platinum-resistant ovarian cancer based on the prespecified interim data analysis from Part 2a of the… Filing
- Mar 26, 2026ResultsReleased financial results. Filing
- Jan 9, 2026AnnouncementThe Company provided a corporate update and highlighted key milestones and expected momentum in the azenosertib development program for 2026. 2025 Accomplishments • Completed enrollment in DENALI Part 2a, supporting registration-intended development of azenosertib. Filing
- Dec 15, 2025LeadershipReported a change among its top officers or directors, or their pay. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Zentalis Pharmaceuticals financials
Famous investors that hold ZNTL
3 of the 50 well-known investors we track reported holding ZNTL in their latest 13F filing. The largest position is Ken Griffin's, worth $12.4M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 4.49M | $12.4M | 0.0% | +95% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 1.50M | $4.2M | 0.0% | -7% |
| Israel Englander · Millennium Management | Q3 2026 | 477,824 | $1.3M | 0.0% | -28% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named ZNTL in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | 5AM Opportunities II (GP), LLC | 13G/A | 4.0% |
| Nov 16, 2026 | Squadron Master Fund LP | 13G/A | 7.3% |
| Nov 16, 2026 | 5AM Opportunities II (GP), LLC | 13G/A | 4.0% |
| Nov 16, 2026 | Squadron Master Fund LP | 13G/A | 7.3% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 4.1% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 4.1% |
Questions about Zentalis Pharmaceuticals, Inc. (ZNTL) stock
Who owns the most ZNTL stock?
The largest reported owner of Zentalis Pharmaceuticals, Inc. (ZNTL) is 5AM Venture Management, LLC, with 5.6% of the company. In total, 114 funds and institutions reported holding ZNTL at the end of Q2 2026, together about 67% of the shares. See the largest owners.
Are ZNTL insiders buying or selling?
In the last 12 months, ZNTL insiders reported 2 open-market purchases worth $22.9M and 10 sales worth $10.1M. The latest trade was on Aug 14, 2026. See every trade.
What is the short interest in ZNTL?
As of Oct 30, 2026, 5.04M ZNTL shares were sold short, 7.0% of the shares outstanding, down 15.9% from the report before. At the average daily volume of 1.44M shares, buying them all back would take about 3.5 trading days (days to cover). See the history.
Which famous investors hold ZNTL?
3 of the 50 well-known investors we track reported ZNTL in their latest 13F filing, including Ken Griffin, Jim Simons, Israel Englander. The largest position is worth $12.4M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.